Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 6Neoplasms 3Neoplasm Metastasis 3Neuroendocrine Tumors 2Neuroectodermal Tumors, Primitive 2Glioblastoma 2Carcinoma, Renal Cell 2Uterine Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Perivascular Epithelioid Cell Neoplasms 1Pancreatic Neoplasms 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Hamartoma Syndrome, Multiple 1Gliosarcoma 1Endometrial Neoplasms 1Castration-resistant Prostate Cancer 1Castrate-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Breast Diseases 1Brain Neoplasms 1Angiomyolipoma 1Advanced Solid Tumor 1

Interventions

Sirolimus 3Everolimus 2dactolisib 1Physical Examination 1Mastectomy, Subcutaneous 1Mastectomy 1Fluorodeoxyglucose F18 1Colonoscopy 18-(6-methoxypyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethylphenyl)-1,3-dihydroimidazo(4,5-c)quinolin-2-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hamartoma Syndrome, Multiple × dactolisib × Clear all
NCT00620594 2020-12-09

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Novartis

Phase 1 Completed
183 enrolled
Breast

Breast Diseases, Breast Neoplasms, Hamartoma Syndrome, Multiple, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡